(Q23917803)

NIOSHTIC-2

29 March 2020

pharmaceutical industry

1 reference

29 March 2020

1

0 references

Raymond E. Biagini

5

object named as

Raymond E. Biagini

0 references

author name string

Mary E. Luken

2

0 references

Michael Breitenstein

3

0 references

John A. Krueger

4

0 references

language of work or name

English

0 references

publication date

31 May 1989

0 references

number of pages

11

1 reference

on focus list of Wikimedia project

inferred from page(s)

published in

Toxicology

0 references

volume

56

0 references

issue

1

0 references

page(s)

107-117

0 references

107-17

0 references

Wikimedia–NIOSH collaboration

0 references

cites work

A benzylamine oxidase distinct from monoamine oxidase B--widespread distribution in man and rat.

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Allylamine cardiotoxicity--IV. Metabolism to acrolein by cardiovascular tissues

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

The role of acrolein in allyl alcohol-induced lipid peroxidation and liver cell damage in mice

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Enhancement of the embryotoxicity of acrolein, but not phosphoramide mustard, by glutathione depletion in rat embryos in vitro

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Influence of hydralazine consumption on allylamine induced myocardial fibrosis and hypertrophy in rats.

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Coronary and thyroid arteriopathy induced by allylamine and beta-aminopropionitrile

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Biotransformation of the cardiovascular toxin, allylamine, by rat and human cardiovascular tissue

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Allylamine cardiotoxicity: I. Sequence of pathologic events

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Allylamine cardiovascular toxicity: V. Tissue distribution and toxicokinetics after oral administration.

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Allylamine cardiovascular toxicity: VI. Subcellular distribution in rat aortas

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Comparative toxicity of the cardiovascular toxin allylamine to porcine aortic smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Binding of [14C] allylamine to isolated mitochondria from rat heart and aorta

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Allylamine cardiovascular toxicity

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Conversion of allyl alcohol into acrolein by rat liver

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

The toxicity of allylamines

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021

Myocarditis produced by allylamines. Experimental

1 reference

https://api.crossref.org/works/10.1016%2F0300-483X%2889%2990216-3

7 January 2021